China VenturesChina Ventures 中华创投协会DEAL MARKETPLACE
Venture

13 Nov 2026China Ventures证券时报 securities times

Hisun licenses Xuanjing's siRNA platform for cardiovascular and metabolic targets

Chinese drugmaker Hisun Pharmaceutical has licensed Xuanjing Bio's liver-targeting GalNAc delivery platform and the preclinical siRNA candidate RGN6669 for cardiovascular, metabolic and respiratory disease targets.

Hisun licenses Xuanjing's siRNA platform for cardiovascular and metabolic targets
Image: China Ventures

What happened

Zhejiang Hisun Pharmaceutical signed a small-nucleic-acid licensing agreement with Suzhou Xuanjing Bio and its Beijing subsidiary on 13 November. Xuanjing grants rights to its liver-targeting GalNAc delivery platform against specified targets in cardiovascular, metabolic and respiratory disease, and licenses RGN6669, an early preclinical liver-targeted siRNA candidate.

The numbers

  • Signing: 13 November.
  • Assets: GalNAc delivery platform and RGN6669.
  • Therapeutic areas: cardiovascular, metabolic and respiratory.
  • Financial terms: not disclosed.

Why it matters

This is a platform deal, not a single-asset purchase. Hisun gets a modality it can apply across targets without building early discovery, and Xuanjing gets a licensee that can develop and commercialise in China's largest chronic-disease markets. siRNA is moving from oncology hype into cardiovascular and metabolic disease, where patient numbers and payer pressure are both large.

The counter-argument is that RGN6669 is preclinical, so the deal is a bet on delivery rather than on data. Undisclosed terms make it impossible to judge the split of risk. The strategic point stands: Chinese pharma is buying platform access, which lets biotechs monetise repeatedly rather than once.

What to watch

  • IND filing and first clinical data for RGN6669.
  • Any disclosure of upfront and milestone terms.
  • Further Xuanjing platform licences in other therapeutic areas.

Original source: NetEase · 13 Nov 2026

All insights ↗